PEPTIDE GUIDE

What Is Pancragen?

Pancragen is an experimental four-amino-acid peptide usually identified as lysine-glutamic acid-aspartic acid-tryptophan, abbreviated KEDW. It comes from the Russian short-peptide bioregulator programme and is associated with the endocrine pancreas, the part of the organ that produces insulin and other hormones controlling blood glucose.

Unlike several lesser-known bioregulators, Pancragen has research at multiple levels. Studies include cultured pancreatic tissue, rats with chemically induced diabetes, old female rhesus monkeys and one small report involving older people with type 2 diabetes. The human study was not a modern randomised, placebo-controlled trial and is too limited to establish treatment benefit.

Pancragen is not an approved diabetes medicine. It should not be presented as a substitute for established glucose monitoring, lifestyle measures or prescribed treatment.

Research statusPreclinical research plus one small, poorly reported human study
Compound typeExperimental four-amino-acid peptide
Human evidenceOne small non-randomised report in older adults
ApprovalNot approved by FDA, MHRA or EMA
Last reviewedOctober 2026
THE SHORT ANSWER

Pancragen is a synthetic tetrapeptide generally reported as KEDW. Laboratory studies report changes in pancreatic-cell differentiation genes and tissue outgrowth. Rat experiments reported effects on glucose, pancreatic morphology and selected blood-vessel measurements. Two very small studies in old rhesus monkeys found changes in glucose, insulin and C-peptide responses. One poorly reported study in 33 older people with type 2 diabetes reported improved glucose and insulin-related measurements, but lacked the design and reporting needed for a reliable clinical conclusion. No large independent trial has established effectiveness, long-term safety or superiority to approved treatment.

What is Pancragen made from?

The reported sequence is:

`Lys-Glu-Asp-Trp (KEDW)`

These names refer to lysine, glutamic acid, aspartic acid and tryptophan. A tetrapeptide contains four amino-acid residues connected by three peptide bonds. Tryptophan has a relatively large aromatic side chain, while lysine is usually positively charged and glutamic and aspartic acid are usually negatively charged under biological conditions.

Some indexed records list an amidated form, Lys-Glu-Asp-Trp-NH2, while others describe the free-acid tetrapeptide. Amidation changes the chemical group at the peptide's final end and can affect charge, stability and biological behaviour. Studies and commercial material should therefore specify which form was tested rather than treating every KEDW preparation as identical.

What does pancreatic bioregulator mean?

The pancreas has two broad roles. Its exocrine tissue releases digestive enzymes into the intestine. Its endocrine islets release hormones into blood. Beta cells make insulin, which helps move glucose out of the circulation, while alpha cells make glucagon, which can raise blood glucose.

Pancragen was developed within a programme proposing that short sequences derived from the analysis of organ peptide preparations could regulate their associated tissue. That origin explains the name, but it does not prove selective delivery to the pancreas.

A targeting claim needs biodistribution data showing intact KEDW in pancreatic tissue, identification of the cells that take it up and evidence of engagement with a defined target. No published human study supplies those measurements.

What did the rat tissue-culture study find?

A 2006 paper tested Pancragen, Prostamax, Cardiogen and Bronchogen in organotypic cultures made from pancreas, prostate, heart and lung tissue from young and old rats. An organotypic culture keeps small pieces of tissue alive outside the body so that some local cell relationships remain intact.

At a reported concentration of 0.05 nanograms per millilitre, each peptide stimulated growth around the tissue associated with its name. This concentration describes a laboratory condition and is not guidance for human use.

Outgrowth can reflect cell migration, proliferation or extension of cellular structures. It does not show that functional insulin-producing beta cells formed, that glucose control improved or that a damaged pancreas regenerated. Removed tissue cannot model digestion, circulation, clearance or whole-body toxicity.

What did the pancreatic-cell differentiation research examine?

A study using cultures of human embryonic pancreatic cells measured genes involved in cell differentiation. Differentiation is the process through which a less specialised cell develops features of a particular cell type.

Pancragen increased expression of CXCL12 and HOXA3, two signalling or transcription-related factors whose measured levels had fallen in later-passage cultures. Later passage means the cells had been repeatedly grown and transferred, a laboratory process sometimes used as a model of cellular ageing.

Another paper examined promoter methylation and expression of PDX1, PAX6 and NGN3. These genes help guide pancreatic development and endocrine-cell identity. Promoter methylation is a chemical marking of DNA that can influence whether a gene is available for transcription. The authors reported correlations among culture age, KEDW exposure, methylation and gene expression.

These studies concern molecular markers in cultured cells. They do not demonstrate production of mature beta cells, sustained insulin release or safe regeneration in a person.

Does gene expression prove beta-cell regeneration?

No. PDX1, PAX6 and NGN3 participate in pancreatic development, but a change in their RNA or promoter methylation is several steps away from a working beta cell. Researchers would need to show appropriate cell identity, glucose-sensitive insulin secretion, survival and integration with blood vessels and nerves.

The direction and timing of developmental genes also matter. Too much or poorly timed activity can create immature or mixed cell states. Cell cultures lack the complete hormonal and immune environment of a living pancreas.

The findings support further mechanism research. They do not establish that Pancragen restores beta-cell mass in type 1 or type 2 diabetes.

What happened in rats with experimental diabetes?

A 2007 paper examined pancreatic morphology and function in rats with experimental diabetes. The abstract reports effects on insulin and glucagon production, cell proliferation, apoptosis and structural features of pancreatic tissue. Apoptosis is an orderly process through which cells dismantle themselves.

A separate study used streptozotocin to create diabetes in Wistar rats. Streptozotocin damages insulin-producing beta cells, producing a model of severe insulin deficiency. The researchers reported that orally administered Pancragen lowered blood glucose during treatment. In another arm, intramuscular administration normalised adhesion of cells lining mesenteric capillaries but did not change capillary permeability. The mesentery supports the intestines and contains their blood vessels.

These findings relate to a chemically induced rat model. Streptozotocin diabetes does not reproduce the autoimmune process of human type 1 diabetes or the combined insulin resistance and progressive beta-cell dysfunction of typical type 2 diabetes.

Why do the blood-vessel findings matter?

Diabetes can damage small and large blood vessels over time. Endothelial cells line the inside of vessels and regulate clotting, inflammation and movement of material between blood and tissues. Abnormal adhesion can encourage inflammatory cells to attach to the vessel wall.

Normalised adhesion in an early rat model may suggest an effect on endothelial behaviour. The absence of a change in permeability shows that related vascular measurements did not move together.

The experiment did not examine human complications such as retinopathy, kidney disease, neuropathy, heart attack or stroke. A cellular vessel measurement cannot substitute for those outcomes.

What was found in old rhesus monkeys?

One study compared old female rhesus monkeys with younger animals during a glucose-tolerance test. Old monkeys cleared glucose more slowly and showed higher early peaks of insulin and C-peptide. C-peptide is released alongside insulin and is used as a marker of insulin produced by the pancreas.

After the reported ten-day experimental exposure to Pancragen, old monkeys cleared glucose faster and showed insulin and C-peptide patterns closer to those of young animals. Part of the reported effect remained three weeks after exposure ended.

This is more relevant to humans than a rodent cell model because rhesus monkeys share more metabolic biology with us. It remains a small animal experiment without the scale needed to assess uncommon adverse effects or durable prevention of diabetes.

How did Pancragen compare with glimepiride in monkeys?

A follow-up involved nine old female rhesus monkeys aged 20 to 25 years. Five received Pancragen and four received glimepiride during the research protocol. Glimepiride is a sulfonylurea medicine that lowers glucose by stimulating pancreatic insulin release.

Both groups showed lower basal glucose. The abstract reports that Pancragen also normalised insulin and C-peptide measurements. With only five and four animals, the comparison is extremely vulnerable to individual variation. It cannot establish equivalence or superiority to glimepiride.

The study also used clinically healthy old monkeys with impaired age-related glucose handling, not a representative population of people with established type 2 diabetes and its associated conditions.

What human evidence exists?

A 2011 report included 30 healthy older people and 33 older people with type 2 diabetes. In the diabetic group, the authors reported lower fasting glucose, improved glucose-tolerance-test measurements, lower plasma insulin and a lower insulin-resistance index after Pancragen. A glucose-tolerance test measures how the body handles a standard glucose load over time.

This is human evidence, but it is weak. The accessible report does not describe secure random allocation, placebo control, masking, a preregistered primary outcome or adequate adverse-event monitoring. Healthy older participants are not an appropriate treatment-control group for people with diabetes. The small sample also makes chance findings and baseline differences harder to exclude.

Lower insulin alongside lower glucose could be consistent with improved insulin sensitivity, but an index calculated from glucose and insulin is an indirect estimate. The study did not establish durable glycated haemoglobin improvement, fewer complications or reduced mortality. Glycated haemoglobin, written HbA1c, reflects average glucose exposure over roughly two to three months.

Why is one small human study insufficient?

Small uncontrolled or poorly controlled studies often overestimate effects. Participants may change diet, activity or medication during observation. Glucose also varies with illness, stress, sleep and measurement conditions. Without randomisation and a credible comparison group, these influences can be mistaken for a treatment effect.

Masking matters because knowledge of treatment can affect behaviour and reporting. Prespecifying one main outcome reduces the risk of highlighting whichever measurement happens to improve. Independent replication tests whether a result depends on a particular laboratory, population or analytical decision.

No later large independent Pancragen trial has resolved these limitations.

Does Pancragen treat type 1 diabetes?

There is no reliable evidence that it does. Type 1 diabetes is an autoimmune condition in which the immune system destroys beta cells. Reversing it would require preservation or replacement of insulin-producing cells and control of the autoimmune attack.

Streptozotocin-treated rats model beta-cell loss but not the full human immune process. Gene-expression changes in cultured pancreatic cells do not show that new beta cells survive immune attack or produce enough insulin in a person. People with type 1 diabetes require insulin; stopping it can cause life-threatening diabetic ketoacidosis.

Does Pancragen treat type 2 diabetes?

The single human report raises a hypothesis but does not establish treatment. Type 2 diabetes combines insulin resistance with progressive difficulty producing enough insulin. It also increases cardiovascular, kidney, eye and nerve risks.

An effective medicine must show reliable glucose control and acceptable safety in well-designed trials. Longer studies examine HbA1c, hypoglycaemia, weight and complications. Approved medicines have condition-specific evidence and regulated manufacturing. Pancragen does not have a comparable development programme.

Is the DNA-binding mechanism established?

Computational work has modelled KEDW binding near an ACCT DNA sequence. Docking is a computer prediction of possible molecular fit. It does not show that intact Pancragen reaches the human pancreatic-cell nucleus or binds that sequence among billions of DNA bases.

The methylation studies demonstrate associations between peptide exposure and molecular measurements in culture. They do not prove direct causation or a unique target. A complete mechanism would require physical binding, target-engagement and loss-of-function experiments connecting the interaction to glucose-responsive insulin secretion.

What is known about absorption and stability?

No adequate human pharmacokinetic study has measured intact KEDW after administration. Peptidases in the digestive tract, blood and tissues can split peptide bonds. Amidation may influence stability, which makes precise product identity important.

A glucose change after oral exposure in rats does not reveal how much intact peptide entered circulation. Metabolites or indirect signals from the intestine could contribute. Human bioavailability, pancreatic concentration, half-life and route of clearance remain unknown.

What is known about safety?

The small human report does not provide a sufficient safety record. A glucose-lowering compound could theoretically cause hypoglycaemia, meaning glucose falls too low, particularly alongside insulin or other diabetes medicines. That risk has not been quantified for Pancragen.

Research would also need to examine immune reactions, liver and kidney effects, pancreatic inflammation, cell proliferation and interactions with medicines. Developmental gene and chromatin effects make long-term and off-target assessment necessary.

Product quality is a separate concern. A label cannot prove whether the material is free-acid KEDW or an amidated form, nor establish content, sterility or freedom from bacterial endotoxins. Endotoxins can provoke severe inflammation even without living bacteria.

How is Pancragen synthesised and checked?

KEDW can be assembled through solid-phase peptide synthesis. Protected amino acids are joined in order while the chain remains attached to a resin. Temporary protecting groups limit unintended reactions. The completed peptide is released, deprotected and purified.

Mass spectrometry can confirm molecular mass and help distinguish amidated from free-acid material. Fragmentation can add sequence information, while chromatography separates the target peptide from incomplete chains and related impurities. Further testing may assess content, water, counterions, residual solvents and stability.

Material for regulated sterile research would require batch consistency, potency, particle, sterility and endotoxin controls. This explanation is not a manufacturing protocol.

How was Pancragen developed?

PeriodDevelopment
1970s onwardSoviet and Russian programmes investigated tissue-derived peptide preparations
2006Organotypic rat-tissue research reported pancreas-associated outgrowth
2007Rat experimental-diabetes papers reported morphology, glucose and vascular findings
2011One small study reported metabolic measurements in older people
2012 to 2015Cell differentiation, methylation and old-monkey studies expanded the preclinical record
2017A nine-monkey comparison with glimepiride was indexed
Through October 2026No large randomised independent human trial was identified

Is Pancragen approved?

No. Pancragen is not approved by the United States Food and Drug Administration, the United Kingdom Medicines and Healthcare products Regulatory Agency or the European Medicines Agency.

How strong is the evidence overall?

QuestionBest available evidenceDefensible conclusion
Does Pancragen affect pancreatic cultures?Human and rat cell or tissue studiesSelected growth, gene and methylation measures changed
Does it affect experimental diabetes?Rat studiesGlucose, tissue and vascular changes were reported
Does it affect primate glucose handling?Two very small studies in old female monkeysMetabolic changes were reported
Does it treat human type 2 diabetes?One small, poorly controlled reportNot established
Does it treat type 1 diabetes?No relevant human trialNot established
Is it safe in people?Inadequate human reportingUnknown
Is it approved?No FDA, MHRA or EMA approvalNo
FREQUENTLY ASKED QUESTIONS

Frequently asked questions

What is Pancragen?

It is an experimental tetrapeptide associated with pancreatic and glucose-regulation research.

What is its sequence?

It is usually reported as Lys-Glu-Asp-Trp, abbreviated KEDW. Some papers specify an amidated form.

Does Pancragen lower blood sugar?

Reductions were reported in animals and one weak human study, but reliable clinical effectiveness has not been established.

Does it regenerate beta cells?

No evidence demonstrates functional beta-cell regeneration in people.

Has Pancragen been compared with a diabetes medicine?

Five old monkeys receiving Pancragen were compared with four receiving glimepiride. This cannot establish clinical equivalence.

Has it been tested in people?

One small, poorly reported study in older adults exists. It was not a definitive clinical trial.

Can Pancragen replace insulin?

No. There is no evidence supporting replacement of prescribed insulin.

Is Pancragen known to be safe?

No adequate human safety profile exists.

Is Pancragen approved?

It is not approved by the FDA, MHRA or EMA.

Research reviewed through October 2026.